Form 4: Eton Pharmaceuticals Director Norbert Riedel Granted Stock Options

Director Norbert Riedel received options to purchase 25,000 shares of Eton Pharmaceuticals stock, vesting quarterly over 12 months.

Summary

• Norbert G. Riedel, a director of Eton Pharmaceuticals, Inc., was granted employee stock options on January 3, 2025.
• The options give Riedel the right to buy 25,000 shares of Eton Pharmaceuticals common stock at an exercise price of $13 per share.
• The options vest equally on a quarterly basis over 12 months, becoming fully vested and exercisable on January 3, 2026.
• The options expire on January 2, 2035.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates confidence in the company's future, but doesn't provide specific financial details.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

NA

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the pharmaceutical sector.
• The vesting schedule of quarterly over 12 months is a typical arrangement to incentivize continued service and performance.
• The exercise price is set at $13.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates